Phase 3 N=203 Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles
Bilateral Nasolabial Fold Wrinkles
Primary: Subject Wrinkle Assessment Responders — 57; 31 participants — p=.00001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=465 PREGNANT Short Cervix Trial
Preterm Delivery · Short Cervix · Short Uterine Cervical Length
Primary: Number of Participants With Birth <=32 6/7 Weeks Gestation. — 36; 21 participants — p=0.020
Phase 3 N=300 Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)
Seasonal Allergic Conjunctivitis
Primary: Bulbar Conjunctival Injection — -1.91; -1.71 units on a scale
Phase 3 N=18,624 A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke — 864; 1014 Participants
Phase 3 N=218 Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles
Bilateral Nasolabial Fold Wrinkles
Primary: Subject Wrinkle Assessment Responders — 50; 19 participants — p=<.00001
Phase 3 N=1,085 Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
Essential Hypertension
Primary: Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure. — -37.6; -38.2; -31.5 mmHg — p=<0.001
Phase 3 N=429 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Carcinoid Tumor · Malignant Carcinoid Syndrome
Primary: Progression Free Survival (PFS) as Per Adjudicated Central Radiology Review — 16.43; 11.33 Months
Phase 3 N=436 Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia
Hypercholesterolemia
Primary: Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg…
Phase 3 N=2,121 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
Diabetes Mellitus, Type 2
Primary: Frequency of Patients With Adverse Events (AEs) — 1253; 465; 57; 23 Participants
Phase 3 N=570 Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes
Type 2 Diabetes
Primary: Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c) — 7.90; 7.94; 7.10; 7.55 percent — p=<0.0001
Phase 3 N=100 A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)
Atherosclerosis · Coronary Artery Disease
Primary: Cardiac Events (Composite) — 1.0 percentage of participants
Phase 3 N=532 Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women
Hot Flashes
Primary: Change From Baseline in Average Daily Frequency of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo — -6.8…
Phase 3 N=169 Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
Lymphoma
Primary: Progression-Free Survival (PFS) — 4.8; 3.7; 1.8 months — p=<0.0001
Phase 3 N=402 Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging
Diagnostic Imaging · Central Nervous System Diseases
Primary: Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic…
Phase 3 N=337 A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint — -24.3; -23.7; -24.3 units on a scale — p=0.999